Search Results
Your search for AT matches 29010 pages
Showing 10201 - 10250Geraldine Jacobson, MD, MPH, MBA, FASTRO, Elected as Future Chair of ASTRO
The members of the American Society for Radiation Oncology (ASTRO) have elected four new officers to ASTRO’s Board of Directors. Geraldine Jacobson, MD, MPH, MBA, FASTRO, will begin her term as President-Elect in October during ASTRO’s 62nd Annual Meeting, alongside Gopal K. Bajaj, MD, MBA,...
Can Radiotherapy Be Omitted for Some Patients With PET-Negative, Early-Stage Unfavorable Hodgkin Lymphoma?
The overwhelming majority of patients with early-stage unfavorable Hodgkin lymphoma may no longer require radiotherapy to treat their disease, according to data presented during the virtual edition of the 25th European Hematology Association (EHA) Annual Congress.1 The findings of the randomized,...
Incorporating Immunotherapy Into Treatment of Early-Stage NSCLC
There is a strong rationale for incorporating immunotherapy into the treatment of early-stage non–small cell lung cancer (NSCLC), given the breakthrough results with PD-1 checkpoint inhibitors as monotherapy, combined with immunotherapy, or combined with chemotherapy in advanced-stage NSCLC. As...
Juanita L. Merchant, MD, PhD, Appointed to Ludwig Institute’s Scientific Advisory Committee
Ludwig Cancer Research recently welcomed Juanita L. Merchant, MD, PhD, to the Scientific Advisory Committee of the Ludwig Institute for Cancer Research. Dr. Merchant is a practicing clinician and an accomplished researcher at the University of Arizona, Tucson, where she is Professor and Chief of...
Measuring the Impact of the Plunge in Cancer Screenings During the COVID-19 Pandemic
As outbreaks of the COVID-19 pandemic spiked across the country earlier this year, federal health officials and cancer societies advised people to delay seeking routine cancer screenings, including mammograms and colonoscopies, to keep them out of medical centers and away from potential exposure to ...
Multiple Lesions Not a Contraindication for Cosmetically Acceptable Lumpectomy
More than 70% of women with multiple tumors in a single breast reported good or excellent satisfaction with the cosmetic results of breast-conserving therapy, Alliance (ACOSOG) Z11102 investigators reported at the 2020 American Society of Breast Surgeons (ASBrS) Virtual Scientific Session.1 In...
Memorial Sloan Kettering Launches Women in Science Endeavor
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of the Marie-Josée Kravis Women in Science Endeavor (WiSE) to provide financial and professional support to women scientists pursuing biomedical research at MSK, pledging its commitment to gender equity in science and ...
A First-Generation Daughter of Immigrants, Gita Suneja, MD, Holds Community Service in High Esteem
Radiation oncologist Gita Suneja, MD, was born and reared in St. Louis, the first-generation daughter of two Indian immigrants. “My father came to the United States to pursue a degree in engineering and decided to remain here, feeling it offered greater opportunities for the family,” Dr. Suneja...
Fred Hutch Announces New Additions and Leadership to Board of Trustees
Fred Hutchinson Cancer Research Center announced the addition of two new members to its Board of Trustees, along with a new Chair and Vice Chair. Kathy Surace-Smith, JD, will take over the Board Chair position from Matt McIlwain, MBA, who now becomes immediate Past Chair. Ms. Surace-Smith, who is...
SNMMI Names Alan B. Packard, PhD, as President, and Richard L. Wahl, MD, as President-Elect
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2020 Virtual Annual Meeting on July 11–14, during which officers for the current term were elected, including Alan B. Packard, PhD, as President, and Richard L. Wahl, MD, as President-Elect. Raising Recognition “SNMMI’s strength ...
Pediatric Hematologist/Oncologist Yoram Unguru, MD, MS, MA, Explains the Economic Origins of Drug Shortages and Other Ethical Issues
Improvements in protocol-driven clinical trials and supportive care for children and adolescents with cancer have markedly reduced mortality rates over the past 5 decades. Yet, along with clinical advances, oncologists and their young patients with cancer face a host of ethical issues, made more...
Increased Time to Breast Cancer Surgery May Not Impact Overall Survival for Patients With Early-Stage Disease
A new study published by Minami et al in the Journal of the American College of Surgeons found that longer time from diagnosis to surgical treatment did not lower overall survival in women with early-stage breast cancer. These findings may be reassuring for women with early-stage breast cancer who...
A Brief Primer on Managing Anxiety in Older Adults With Cancer
Cancer-related anxiety has negative impacts on emotional, physical, and social well-being, with data indicating older patients are likely to remain undiagnosed, leading to poor outcomes. In this installment of The ASCO Post’s Integrative Oncology series, Drs. Trevino, Saracino, and Roth highlight...
First-Line Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
In a phase Ib trial reported in the Journal of Clinical Oncology, Richard S. Finn, MD, and colleagues found that the combination of lenvatinib and pembrolizumab produced durable responses in patients with unresectable hepatocellular carcinoma who had received no prior systemic chemotherapy. As...
FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More
Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...
Combination Immunotherapy in Advanced Biliary Tract Cancers
In a subgroup analysis of an Australian phase II trial reported in JAMA Oncology, Klein et al found that the combination of nivolumab and ipilimumab was active in patients with advanced biliary tract cancers. Study Details The phase II trial is enrolling patients with advanced rare cancers. The...
Anti-CD30 CAR T-Cell Therapy for Patients With Relapsed or Refractory Hodgkin Lymphoma
In a pooled analysis of two parallel single-center phase I/II studies reported in the Journal of Clinical Oncology, Ramos et al found that anti-CD30 chimeric antigen receptor (CAR) T-cell therapy produced responses in a high proportion of patients with relapsed or refractory Hodgkin lymphoma. As...
Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer
In the phase III HALO 109-301 trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the addition of pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel plus gemcitabine (AG) did not improve overall survival or progression-free survival in patients...
FDA Grants Accelerated Approval to Belantamab Mafodotin-blmf for Pretreated Patients With Relapsed or Refractory Multiple Myeloma
On August 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep), an anti-B-cell maturation antigen antibody-drug conjugate, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies,...
Karen E. Knudsen, MBA, PhD, on the Challenges of Using Telehealth in Cancer Care
Karen E. Knudsen, MBA, PhD, of the Sidney Kimmel Cancer Center at Jefferson Health, summarizes a panel she moderated on telehealth, which included discussion of usage in urban vs rural populations, preventing the technology from becoming a new source of disparities in cancer care, and uncertainties ...
ASCO Guideline Supports Continued Use of Dexamethasone for Patients Receiving Checkpoint Inhibitors and Emetogenic Chemotherapy
The ASCO guideline on the use of antiemetics has been updated to include new anticancer agents, antiemetics, and regimens.1 The guideline also addresses a growing concern among some oncologists that corticosteroids and their immunosuppressive abilities could potentially compromise the efficacy of...
Severe Hearing Impairment Associated With Neurocognitive Deficits in Childhood Cancer Survivors
Findings from a report published by Bass et al in JAMA Oncology show that childhood cancer survivors with severe hearing loss are at a significant increased risk for neurocognitive deficits, independent of what type of therapy they receive. This study is the first to objectively measure hearing and ...
Risk of Breast Cancer After Total-Body Irradiation and Blood or Marrow Transplantation for Hematologic Malignancies
In an analysis from the Blood or Marrow Transplantation Survivor Study reported in the Journal of Clinical Oncology, McDonald et al found that total-body irradiation in women undergoing autologous or allogeneic blood or marrow transplantation for hematologic malignancies was associated with an...
Second-Look Surgery Plus HIPEC vs Surveillance for Patients at High Risk for Colorectal Peritoneal Metastases
In a French phase III trial (PROPHYLOCHIP–PRODIGE 15) reported in The Lancet Oncology, Goéré et al found that second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) did not improve disease-free survival vs standard surveillance in patients at high risk of developing colorectal...
Role of TP53 Mutations on Disease Severity in Myelodysplastic Syndromes
Considered the “guardian of the genome,” TP53 is the most commonly mutated gene in patients with cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells. When TP53 is mutated, the protein made from this gene, called p53, can no longer...
Nationwide Trends Show Fewer Patients With Cancer in the United States Seeking Care Since Start of the COVID-19 Pandemic
Research published by London et al in JCO Clinical Cancer Informatics found significant decreases nationwide in the number of patients seen for cancer-related care as the COVID-19 pandemic progressed during the first few months of 2020. The most significant decline was seen in encounters related to ...
Does Adding Neoadjuvant Chemohormonal Therapy to Surgery in Patients With Localized High-Risk Prostate Cancer Improve Biochemical Progression–Free Survival?
As reported in the Journal of Clinical Oncology by Eastham et al, the phase III CALGB 90203/Alliance trial has shown no improvement in 3-year biochemical progression-free survival (BPFS) with the addition of neoadjuvant chemohormonal therapy to radical prostatectomy in patients with localized...
Pyrotinib for Pretreated Patients With HER2-Mutated Advanced NSCLC
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Zhou et al found that pyrotinib produced durable responses in patients with HER2-mutated advanced non–small cell lung cancer (NSCLC) who had received prior platinum-based chemotherapy. Study Details The multicenter study...
FDA Approves Tafasitamab-cxix Combined With Lenalidomide to Treat Adults With Relapsed/Refractory DLBCL
On July 31, the U.S. Food and Drug Administration (FDA) approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from low-grade...
Overcoming the Challenges of Improving Psychosocial Care for Patients With Cancer
Although the United States spends billions of dollars each year on cancer research, very little of that funding is dedicated to mental health research in patients with cancer, despite the fact that cancer survivors have a six-time higher risk for psychological disability than people without...
Pan-BET Bromodomain Inhibitor Plus Enzalutamide in Advanced Prostate Cancer
A new multi-institution, dose-determining clinical trial of a compound for patients with metastatic, castration-resistant prostate cancer showed the combination “demonstrated acceptable tolerability and potential efficacy,” reported Aggarwal et al in Clinical Cancer Research. The phase Ib/IIa study ...
ESMO Issues Consensus on the Management of Patients With Cancer During the COVID-19 Pandemic
A European Society for Medical Oncology (ESMO) interdisciplinary expert consensus paper on how to manage patients with cancer during the COVID-19 pandemic was published by Giuseppe Curigliano, MD, PhD, and colleagues in Annals of Oncology. The guidance encourages medical oncologists worldwide not...
NALA Trial: Neratinib/Capecitabine vs Lapatinib/Capecitabine for Pretreated Patients With HER2-Positive Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Cristina Saura, MD, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with neratinib/capecitabine vs lapatinib/capecitabine in patients with HER2-positive metastatic breast cancer who had received...
Sorafenib Maintenance After Allogeneic HCT in Patients With FLT3-ITD–Positive AML
In the German-Austrian phase II SORMAIN trial reported in the Journal of Clinical Oncology, Burchert et al found that maintenance treatment with sorafenib vs placebo was associated with significantly prolonged relapse-free survival after allogeneic hematopoietic stem cell transplantation (HCT) in...
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
On July 30, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive...
Addition of Pazopanib to Preoperative Chemoradiotherapy in Children and Adults With Soft-Tissue Sarcoma
In an interim analysis of a joint Children’s Oncology Group and NRG Oncology phase II trial (ARST1321) reported in The Lancet Oncology, Aaron R. Weiss, DO, and colleagues found that the addition of pazopanib to preoperative chemoradiotherapy significantly increased the rate of pathologic...
Does Periodontal Disease Increase the Risk of Colorectal Cancer?
Periodontal disease was associated with an increased risk of two precursors of colorectal cancer, according to results of a study published by Lo et al in Cancer Prevention Research. “Periodontal disease is prevalent among adults, with periodontitis affecting more than 40% of the U.S. population,”...
American Cancer Society Updates Guideline for Cervical Cancer Screening
An updated cervical cancer screening guideline from the American Cancer Society released today has called for less—and more simplified—screening. The guideline was published by Fontham et al in CA: A Cancer Journal for Clinicians. The updated guideline recommends that individuals with a cervix...
First-Line S-1 Plus Leucovorin and Oxaliplatin vs S-1 Plus Cisplatin in Advanced Gastric Cancer
As reported in The Lancet Oncology by Kang et al, the Japanese-Korean phase III SOLAR trial showed that oral tegafur/gimeracil/oteracil, a combination known as S-1, plus leucovorin and oxaliplatin was associated with a modest but significant improvement in overall survival vs S-1 plus cisplatin in...
Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
As reported in the Journal of Clinical Oncology by Grob et al, the first interim analysis of the phase II KEYNOTE-629 trial has shown that treatment with pembrolizumab resulted in durable responses in patients with recurrent or metastatic cutaneous squamous cell carcinoma. The study supported the...
Top Scientists Share Early Research on Intersection of COVID-19 and Cancer Care at AACR Virtual Meeting
The American Association for Cancer Research (AACR) Virtual Meeting: COVID-19 and Cancer took place from July 20 to 22, 2020, attracting top scientific minds from around the world to present preliminary research on the ever-evolving COVID-19 pandemic and its intersection with cancer care. In an...
Study Finds Lack of Parental Intent to Initiate and Complete HPV Vaccination in the United States
Study results documenting parental hesitancy to begin and complete their child's human papillomavirus (HPV) vaccine series were published by Sonawane et al in The Lancet Public Health. The Centers for Disease Control and Prevention recommends a two-dose HPV vaccination regimen for children if the...
Outcomes With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...
Impact of Pregnancy After Breast Cancer in Women With Deleterious Germline BRCA Mutations
In a retrospective cohort study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, PhD, and colleagues found that pregnancy after breast cancer in women harboring deleterious germline BRCA mutations did not appear to be associated with worsened maternal prognosis or fetal...
Expert Point of View: Antoni Ribas, MD, PhD, and Richard T. Penson, MD
American Association for Cancer Research (AACR) President Antoni Ribas, MD, PhD, of UCLA School of Medicine, Jonsson Comprehensive Cancer Center, Los Angeles, commented on this study with statins and ovarian cancer: “This large study based on the records of more than 10,000 women over a 10-year...
Statin Use Linked to Improvement in Survival in Ovarian Cancer
Lipophilic statin use was associated with a reduced risk of dying of epithelial ovarian cancer in a large observational study. Compared with never users, women with epithelial ovarian cancer who were taking any type of statins had a reduced mortality of 40%, and those taking lipophilic statins had...
Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border
Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic...
Expert Point of View: Michele Teng, PhD
Study discussant Michele Teng, PhD, of QIMR Berghofer Medical Research Institute, Brisbane, Australia, commented: “Cancer immunotherapy is a new pillar of cancer treatment. The aim is to improve the overall survival of patients with cancer, but there is room for improvement, and various...
Anti-TIGIT Antibody Plus Atezolizumab Move Forward in Advanced NSCLC
Tiragolumab, an anti-TIGIT antibody, plus the PD-L1 inhibitor atezolizumab exhibited early clinical activity and was tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer (NSCLC) that was PD-L1–positive and untreated with prior checkpoint...
Are Patients With a Longer-Established Diagnosis of Cancer at Higher Risk for More Severe Infection or Death From COVID-19?
According to research published by Russell et al in Frontiers in Oncology, patients with a longer-established diagnosis of cancer are at increased risk for more severe infection with COVID-19, as well as death from the virus. Patients of Asian ethnicity or who were receiving palliative treatment...
